Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Gold Prices Stabilize in Asian Trade After Sharp Weekly Losses Amid Fed Uncertainty 
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback 
NASA Resumes Cygnus XL Cargo Docking with Space Station After Software Fix 
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast 
U.S. Stock Futures Slip as Markets Brace for Big Tech Earnings and Key Data 
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation 
Starmer’s China Visit Highlights Western Balancing Act Amid U.S.-China Rivalry 
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay 
Wall Street Slides as Warsh Fed Nomination, Hot Inflation, and Precious Metals Rout Shake Markets 
Dollar Holds Firm as Markets Weigh Warsh-Led Fed and Yen Weakness Ahead of Japan Election 
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now 
Asian Stocks Waver as Trump Signals Fed Pick, Shutdown Deal and Tech Earnings Stir Markets 
FDA Lifts REMS Requirement for CAR-T Cell Cancer Therapies 
Keio University researchers have successfully transplanted into a patient with a severe spinal cord injury two million neural progenitor cells derived from other people’s iPS cells as part of a clinical study, offering hope for the paralyzed.
The patient is doing well.
Over the next year, while the patient undergoes rehabilitation, the team of doctors will see how safe and effective the treatment is.
The treatment is designed for patients with “complete paralysis” who are within two to four weeks of sustaining a spinal cord injury, called the subacute phase.
The iPS cells used were stockpiled by Kyoto University’s Center for iPS Cell Research and Application.
While rehabilitation is currently the only effective treatment for a spinal cord injury, the team believes that the transplanted cells could repair damaged neural circuits and create new tissue that can transmit signals from the brain.
The team plans to do the transplant into four more patients with spinal cord injuries.
While Japan’s Ministry of Health, Labor, and Welfare approved this clinical trial in February 2019, the process of finding suitable patients was postponed due to the COVID-19 pandemic.
